2-(1,1-dimethylethyl)-3-methoxy-Phenazine
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Others |
| Catalog number | BBF-05661 |
| CAS | 94822-15-8 |
| Molecular Weight | 266.34 |
| Molecular Formula | C17H18N2O |
Online Inquiry
Specification
| Synonyms | Phenazine, 2-(1,1-dimethylethyl)-3-methoxy-; 2-Methoxy-3-tert-butyl-phenazine; 3-tert-Butyl-2-methoxy-phenazine |
| IUPAC Name | 2-(tert-butyl)-3-methoxyphenazine |
Properties
| Melting Point | 88.5-89.5°C (petroleum ether) |
Reference Reading
1. CO2 Absorption Mechanism by the Nonaqueous Solvent Consisting of Hindered Amine 2-[(1,1-dimethylethyl)amino]ethanol and Ethylene Glycol
Ran Li, Congyi Wu, Dezhong Yang Molecules. 2020 Dec 5;25(23):5743. doi: 10.3390/molecules25235743.
In this work, we studied the CO2 absorption mechanism by nonaqueous solvent comprising hindered amine 2-[(1,1-dimethylethyl)amino]ethanol (TBAE) and ethylene glycol (EG). The NMR and FTIR results indicated that CO2 reacted with an -OH group of EG rather than the -OH of TBAE by producing hydroxyethyl carbonate species. A possible reaction pathway was suggested, which involves two steps. In the first step, the acid-base reaction between TBAE and EG generated the anion HO-CH2-CH2-O-; in the second step, the O- of HO-CH2-CH2-O- attacked the C atom of CO2, forming carbonate species.
2. Ligustrazine monomer against cerebral ischemia/reperfusion injury
Hai-Jun Gao, Peng-Fei Liu, Pei-Wen Li, Zhuo-Yan Huang, Feng-Bo Yu, Ting Lei, Yong Chen, Ye Cheng, Qing-Chun Mu, Hai-Yan Huang Neural Regen Res. 2015 May;10(5):832-40. doi: 10.4103/1673-5374.156991.
Ligustrazine (2,3,5,6-tetramethylpyrazine) is a major active ingredient of the Szechwan lovage rhizome and is extensively used in treatment of ischemic cerebrovascular disease. The mechanism of action of ligustrazine use against ischemic cerebrovascular diseases remains unclear at present. This study summarizes its protective effect, the optimum time window of administration, and the most effective mode of administration for clinical treatment of cerebral ischemia/reperfusion injury. We examine the effects of ligustrazine on suppressing excitatory amino acid release, promoting migration, differentiation and proliferation of endogenous neural stem cells. We also looked at its effects on angiogenesis and how it inhibits thrombosis, the inflammatory response, and apoptosis after cerebral ischemia. We consider that ligustrazine gives noticeable protection from cerebral ischemia/reperfusion injury. The time window of ligustrazine administration is limited. The protective effect and time window of a series of derivative monomers of ligustrazine such as 2-[(1,1-dimethylethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine, CXC137 and CXC195 after cerebral ischemia were better than ligustrazine.
3. Boceprevir
S A Rizza, R Talwani, V Nehra, Z Temesgen Drugs Today (Barc). 2011 Oct;47(10):743-51. doi: 10.1358/dot.2011.47.10.1656503.
Boceprevir is a hepatitis C virus (HCV) serine protease NS3 inhibitor that has recently been approved by the U.S. Food and Drug Administration, the European Medicines Agency and Health Canada for the treatment of chronic genotype 1 HCV infection. It has potent in vitro antiviral activity against HCV genotypes 1a and 1b and is primarily metabolized via the aldoketoreductase pathway with minor cytochrome P450 3A4 metabolism. Boceprevir is well tolerated with few drug-drug interactions which are easy to manage; no dose adjustment is required in patients with hepatic or renal impairment. Phase I trials of boceprevir demonstrated favorable pharmacokinetic, metabolic and safety profiles. Phase II and III trials of boceprevir confirmed the antiviral activity of the drug and its use at a dose of 800 mg three times daily. Clinical trials in treatment-naive and previously treated HCV-infected patients demonstrated a 26% and 45% (respectively) improvement in sustained viral response when boceprevir was added to standard pegylated interferon and ribavirin anti-HCV therapy. Boceprevir is the first-in-class of an exciting new phase of HCV treatment.
Recommended Products
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-03754 | Castanospermine | Inquiry |
| BBF-03755 | Actinomycin D | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
